
Grove Biopharma Highlights Nature Communications Study on Novel MYC and KRAS Degradation Strategy
Grove Biopharma Reports Breakthrough Preclinical Data Showcasing Targeted Degradation of MYC and KRAS Through Its Bionic Biologics Platform Grove Biopharma, a privately held biotechnology innovator, has announced the publication of…












